Blood Res.  2014 Jun;49(2):134-137. 10.5045/br.2014.49.2.134.

Simultaneous presentation of JAK2 V617F mutation-related essential thrombocythemia and B-cell chronic lymphocytic leukemia

• D'Angelo G
• Hotz AM
• Ciambelli
• Pauli S

• KMID: 2172812
• DOI: http://doi.org/10.5045/br.2014.49.2.134

Abstract

No abstract available.

MeSH Terms

Leukemia, Lymphocytic, Chronic, B-Cell*
Thrombocythemia, Essential*

Figure

• 

  Fig. 1 (A) Bone marrow aspirate (May-Grünwald-Giemsa, MGG) showing lymphoid hyperplasia represented by small cells with scant cytoplasm (magnification 400×); (B) Bone marrow biopsy (hematoxylin-eosin) showing lymphoid hyperplasia and simultaneous megakaryocytic hyperplasia, isolated and in groups (magnification 200×); (C) Bone marrow biopsy showing a population of small lymphoid cells that were CD5+ (magnification 200×); and (D) Bone marrow aspirate (MGG) showing large megakaryocyte with hyperlobated nucleus (magnification 1,000×).

• 

  Fig. 2 Pathogenetic hypothesis of the simultaneous presence of myeloid and lymphoid disease. Abbreviation: EPMH-SC, early progenitor multipotential hematopoietic stem cell.

Reference

1. Bethard WF, Block MH, Robson M. Coexistent chronic lymphatic leukemia and polycythemia vera; morphologic and clinical studies with particular reference to unusual iron metabolism. Blood. 1953; 8:934–943. PMID: 13093766.

2. George TI, Horny HP. Systemic mastocytosis. Hematol Oncol Clin North Am. 2011; 25:1067–1083. viiPMID: 22054735.

3. Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005; 130:325–332. PMID: 16042682.

4. Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013; 88:507–516. PMID: 23695894.

5. Hauck G, Jonigk D, Kreipe H, Hussein K. Simultaneous and sequential concurrent myeloproliferative and lymphoproliferative neoplasms. Acta Haematol. 2013; 129:187–196. PMID: 23257916.

6. Chintapatla R, Battini R, Wiernik PH. Chronic lymphocytic leukemia with essential thrombocythemia: asbestos exposure association? Clin Adv Hematol Oncol. 2012; 10:752–755. PMID: 23271264.

7. Tabaczewski P, Nadesan S, Lim SH. Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: a common defective stem cell? Leuk Res. 2009; 33:854–855. PMID: 18849073.

8. Gaillard JB, Carillo S, Henry L, Jourdan E, Lavabre-Bertrand T. Association of myeloproliferative and lymphoproliferative disorders. Clin Adv Hematol Oncol. 2012; 10:756–757. PMID: 23271265.

9. Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev. 2009; 18:2068–2073. PMID: 19531676.

10. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2009; 106:9414–9418. PMID: 19470474.

11. Orozco CA, Acevedo A, Cortina L, et al. The combined expression patterns of Ikaros isoforms characterize different hematological tumor subtypes. PLoS One. 2013; 8:e82411. PMID: 24324784.

12. Henry L, Carillo S, Jourdan E, Arnaud A, Brun S, Lavabre-Bertrand T. Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment. Am J Hematol. 2007; 82:500–501. PMID: 17301972.